Sgc8c was chosen for its ability to target PTK7, which is overexpressed in pancreatic cancer, and for being easier to modify than antibodies, thereby enhancing treatment precision and efficacy. The gene discussed is PTK7; the disease is familial pancreatic carcinoma.